Literature DB >> 3232800

Altered aminoglycoside pharmacokinetics in the critically ill.

M J Beckhouse1, I M Whyte, P L Byth, J C Napier, A J Smith.   

Abstract

We studied prospectively 49 patients being treated in an intensive care unit with aminoglycosides for gram-negative sepsis. Pharmacokinetic data were calculated from three post-dose serum levels using a one-compartment model. Doses required to achieve peak levels between 5 and 10 mg/l with trough levels approximately 1.0 mg/l ranged between 2 and 12 mg/kg per day (mean dose 7 mg/kg per day). During therapy 60% of the patients had a change in their apparent volume of distribution (Vd) of greater than 20%. These patients were likely to have confirmed infection and to be febrile at the start of treatment. Two to three weeks after discharge ten patients were restudied after a single dose of aminoglycoside. There was a reduction in mean Vd from 0.24 to 0.18 l/kg (P less than 0.02). Critically ill patients have significantly larger volumes of distribution and may require larger doses per kilogram of body weight of aminoglycoside to achieve therapeutic concentrations. Due to considerable variation in kinetic parameters, the use of standard doses or dosing nomograms is not recommended.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3232800     DOI: 10.1177/0310057X8801600406

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  16 in total

1.  Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen.

Authors:  Etienne de Montmollin; Lila Bouadma; Nathalie Gault; Bruno Mourvillier; Eric Mariotte; Sarah Chemam; Laurent Massias; Emmanuelle Papy; Florence Tubach; Michel Wolff; Romain Sonneville
Journal:  Intensive Care Med       Date:  2014-04-01       Impact factor: 17.440

Review 2.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

3.  Influence of experimental rat model of multiple organ dysfunction on cefepime and amikacin pharmacokinetics.

Authors:  O Mimoz; A Jacolot; C Padoin; J Quillard; M Tod; K Louchahi; K Samii; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

4.  Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units.

Authors:  K Vandewoude; D Vogelaers; J Decruyenaere; P Jaqmin; K De Beule; A Van Peer; R Woestenborghs; K Groen; F Colardyn
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

Review 5.  Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.

Authors:  Peter De Paepe; Frans M Belpaire; Walter A Buylaert
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 6.  Clinical Pharmacology Studies in Critically Ill Children.

Authors:  Nilay Thakkar; Sara Salerno; Christoph P Hornik; Daniel Gonzalez
Journal:  Pharm Res       Date:  2016-09-01       Impact factor: 4.200

7.  The pharmacokinetics and pharmacodynamics of cisatracurium in critically ill patients with severe sepsis.

Authors:  Xin Liu; Peter S Kruger; Michael Weiss; Michael S Roberts
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

Review 8.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 9.  Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.

Authors:  Nikolas J Onufrak; Alan Forrest; Daniel Gonzalez
Journal:  Clin Ther       Date:  2016-07-20       Impact factor: 3.393

10.  Studies on drug monitoring in thrice and once daily treatment with aminoglycosides.

Authors:  F Konrad; R Wagner; B Neumeister; H Rommel; M Georgieff
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.